Coya Therapeutics, Inc. COYA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.02M | 7.94M | 7.95M | 3.99M | 423.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.02M | 7.94M | 7.95M | 3.99M | 423.50K |
| Cost of Revenue | 16.98M | 15.62M | 16.73M | 13.73M | 13.04M |
| Gross Profit | -8.97M | -7.68M | -8.79M | -9.74M | -12.62M |
| SG&A Expenses | 11.86M | 12.52M | 11.45M | 10.32M | 9.98M |
| Depreciation & Amortization | 19.20K | 23.20K | 27.20K | 27.20K | 27.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.87M | 28.16M | 28.21M | 24.08M | 23.05M |
| Operating Income | -20.85M | -20.22M | -20.27M | -20.09M | -22.62M |
| Income Before Tax | -21.67M | -21.12M | -21.22M | -19.15M | -21.06M |
| Income Tax Expenses | 3.10K | 3.10K | 3.10K | -720.30K | -720.30K |
| Earnings from Continuing Operations | -21.67 | -21.13 | -21.23 | -18.43 | -20.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.67M | -21.13M | -21.23M | -18.43M | -20.34M |
| EBIT | -20.85M | -20.22M | -20.27M | -20.09M | -22.62M |
| EBITDA | -20.83M | -20.20M | -20.24M | -20.06M | -22.59M |
| EPS Basic | -1.07 | -1.15 | -1.27 | -1.11 | -1.24 |
| Normalized Basic EPS | -0.58 | -0.63 | -0.71 | -0.70 | -0.80 |
| EPS Diluted | -1.07 | -1.15 | -1.27 | -1.11 | -1.24 |
| Normalized Diluted EPS | -0.58 | -0.63 | -0.71 | -0.70 | -0.80 |
| Average Basic Shares Outstanding | 79.58M | 72.84M | 66.92M | 66.54M | 65.02M |
| Average Diluted Shares Outstanding | 79.58M | 72.84M | 66.92M | 66.54M | 65.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |